

### ASX ANNOUNCEMENT

19 October 2023

## **Board Roles and Structure**

CardieX Limited (ASX: CDX) (**CardieX**, the **Company**) provides an update on the composition of the Board having reviewed the current Board roles and Company requirements ahead of the coming year.

The Board is seeking to onboard two new independent directors, one Australian based and one US based. The Board is seeking to onboard seasoned directors with experience in consumer health technologies, global healthcare, and corporate governance. The new US based director is anticipated to have significant healthcare industry experience, including a track record of growing consumer health technology products for globally renowned industry leaders and be able to add significant value to the Company's growth path.

Commensurate with the above strategy the Company advises that Ms Lesa Musatto has tendered her resignation as Independent Non-Executive Director of the Company with effect from 18 October 2023, due to her other business commitments. The Board thanks Ms Musatto for her support of the Company and wishes her well for her future endeavours.

The Board will provide further updates on the appointment of the two additional directors in due course.

### Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations Rod Hinchcliffe rod.hinchcliffe@mcpartners.com.au

Media Relations Melissa Hamilton melissa.hamilton@mcpartners.com.au

Investor Relations – USA Matt Selinger Managing Director, Integrous Communications mselinger@integcom.com

### About CardieX

CardieX is a medical technology company that develops and markets non-invasive patient monitoring technologies for assessing vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market leading SphygmoCor<sup>®</sup> vascular biomarker technology. CardieX is listed on the Australian Stock Exchange ("CDX").

Rule 3.19A.3

# Appendix 3Z

### Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	CARDIEX LIMITED
ABN	81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Lesa Maoy Musatto
21 December 2022
18 October 2023

#### **Part 1** – **Director's relevant interests in securities of which the director is the registered holder** *In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

### Number & class of securities

- 150,000 Options at \$0.50 expiring 26 April 2027
- 350,000 Options at \$0.50 expiring 16 December 2027

<sup>+</sup> See chapter 19 for defined terms.

# Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
N/A	N/A

### Part 3 – Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A

<sup>+</sup> See chapter 19 for defined terms.